NCT06717867View on ClinicalTrials.gov

Long-Term PEA Safety Study

PHASE2RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

January 22, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
HealthySafety
Interventions
DIETARY_SUPPLEMENT

Palmitoylethanolamide (PEA)

Levagen™ capsule containing 300mg Palmitoylethanolamide (PEA). 600mg PEA per day.

OTHER

Placebo

Placebo capsules contain 300 mg microcrystalline cellulose (MCC), 600mg per day.

Trial Locations (1)

4006

RECRUITING

RDC Clinical, Brisbane

All Listed Sponsors
collaborator

Gencor Pacific Limited

UNKNOWN

lead

RDC Clinical Pty Ltd

INDUSTRY